Australian (ASX) Stock Market Forum

IVG - Invert Graphite

Jump to new
Re: TIS - Tissue Therapies

I have been wondering the same thing. The sell depth is disappearing too. Strange it has moved more today than after decent news. Hmmmm next week may tell the story.
 
Re: TIS - Tissue Therapies

Wow, as i typed that 61c was almost taken out and buyers building in the high 50's. Should be an interesting close.
 
Re: TIS - Tissue Therapies

Spotty

Looks to have broken over .60 resistance at last. Pity it didn't end on its high, but Monday may prove to be another day.

Interesting that there is no news as yet but perhaps the market is just catching up on what has been a positive first half year.
 

Attachments

  • TIS 1 June eod.gif
    TIS 1 June eod.gif
    18.5 KB · Views: 305
Re: TIS - Tissue Therapies

There was an article in today's Courier-Mail gist of which was that Dr Upton is about to see her work put to the ultimate test with human trials of her wound treatment.

Canadian researchers will test the therapy in August in patients with difficult to heal skin ulcers. The treatment has the potential to speed up the healing of wounds and reduce scarring.

Dr Upton's research has ultimately led to her discovery of a sticky protein called vitronectin which aids in the stimulation of skin cells to migrate over the surface of the wound.

Vitronectin forms the basis of the prouct trademarked VitroGro about to be trialled in Toronto.

"Optimistically, if the trials prove okay, we'd be working towards VitroGro being approved some time in 2008. If we get a dream run, that's possible" Professor Upton said.
 
Re: TIS - Tissue Therapies

Anyone still hold this stock? The previous post was posted about 1 1/2 years ago.

Anyway, they have just been granted their second South African patent.

Would like to hear from someone about their opinion.
 
Re: TIS - Tissue Therapies

I purchased some of this stock just before Christmas. Looks promising to me. I am amazed by the product itself, anything that can help or improve the treatment of wounds and scarring, sounds like a great thing to me.
 
Re: TIS - Tissue Therapies

I am very happy with the progress of this stock in the last few months, as should all LT holders be.

I think this technology is blue sky stuff, and well worth the wait. It's not just another way of doing venous ulcer healing - the common treatment is pressure pads - it's a totally new concept in treatment, far differentiated from the current treatment and imho it'll blow us away with full phase 3 results. Bring it on!

Anyone see that movie with Angelina Jolie, Morgan Freeman where they could bend bulletts and they jumped into this bath that healed things in hours not days? - Imagine that, jump into a bath of TIS's proteins and... hours not days.
 
Re: TIS - Tissue Therapies

Hatchy said:
I think this technology is blue sky stuff, and well worth the wait. It's not just another way of doing venous ulcer healing - the common treatment is pressure pads - it's a totally new concept in treatment, far differentiated from the current treatment and imho it'll blow us away with full phase 3 results. Bring it on!
Click to expand...


I am totally agree with you. I have started to accumulate this stock as I believe VitroGro has a big potential in treating patients with venous ulcers :)

Also, with the release of more positive clinical trial results by June, this stock should start heading North soon. :D
 
Re: TIS - Tissue Therapies

The sp is now $0.20 (2:38pm), which is a big 25% jump!!

Does anyone know what is happening? Is there an announcement about to come out?
 
Re: TIS - Tissue Therapies

Massive moves in this stock over the last few days.
I've been a long time believer in them and have seen the bad times - perhaps that's behind us and we can look forward to the story unfolding.

I can't explain this great jump over the last few days, the granting of patents has happened consistently without this kind of activity.

Perhaps rumours are going around about a possible bid for the tech? Can anyone add any fire to that?

I think the next stage is commercialisation - that's a given - i'm fairly sure that there isn't the money in the kitty to do it without a partner.

I wonder what will be said at tomorrows AGM about the current share price rally. Anyone going that can give a report?
 
Re: TIS - Tissue Therapies

Wow 18 months between posts for TIS, Ive been holding this stock for about 20 months now and happy to finally see some good price movement.
 
Re: TIS - Tissue Therapies

justiceotp said:
Wow 18 months between posts for TIS, Ive been holding this stock for about 20 months now and happy to finally see some good price movement.
Click to expand...

Yes it is encouraging, but i'm nervous at the same time - there's been no real spur for this jump - market news of more patents being granted doesn't add up. Perhaps there's a research house that's done a piece... Who knows.
 
Re: TIS - Tissue Therapies

Some quotes from prof Keith Harding:

The one thing that I have found impressive in working with Tissue Therapies is that they seem to have commitment to understanding the science and managing the development of the product in a structured way that doesn’t go anywhere unless the science is there to support the data.

The one thing that was impressive both from the preclinical data and the early clinical studies is that in the clinical studies particularly, there seemed to be a greater consistency of response in the patients that were exposed to this product, far more consistent than I’ve seen with other biological therapies that I personally have been involved in trialling or evidence that I have reviewed in other capacities.

It is important to recognize that undertaking these studies do require a lot of regulatory hurdles to be overcome and then to find suitable patients but we are confident that we will be able to produce data by first quarter 2011.

The potential for VitroGro if the evidence that emerges supports the data that is already there is enormous.

lthough Tissue Therapies is a small company compared to many of the larger players in this area, the one thing that is impressive is that Tissue Therapies seem to have a genuine interest, focus and passion in trying to provide a sound basis and evaluation of the product that they have. My hope - and I’m not a spokesperson for Tissue Therapies - is that they will continue that focus, they will continue that passion, and I would anticipate that the success of VitroGro will be significant, but I would also hope that it will be the first generation of a series of biologically based therapies that may be developed by this company as it goes forward
 
Re: TIS - Tissue Therapies

Tissue Therapies Financial Data
 Listed ASX 14 March 2004
 Issued Capital (after placements & SPP): 138,201,447 shares
 Share Price: $ 0.36
 Market Cap: $49.7M
 Cash at end Sep. 2010: $ 4.1M
 Cash burn (approx.): $170K per month
 Cash position should be sufficient to get to profitability end CY 2011

I think that there's been a considerable amount of buying in the last week that may be due to the european trials starting.

According to the presentations, and the quotes below we should expect results from that Euro trial 1-2Q 2011.
 
Re: TIS - Tissue Therapies

:)

Hi folks,

TIS ... has had a strong upmove, since early September 2010,
though volumes during this time have been very moderate,
but this is not unusual, as many biotechs have been
in overlooked our market.

Over the past week or so, the price action has formed a
pennant, finishing with a doji (indecision), last Friday.

Our astroanalysis for TIS this week will have us alert for a positive
cycle to bring some news/moves, around 11-12012011.

have a great day

paul

:)

=====
 
Re: TIS - Tissue Therapies

TIS has fallen a bit from it's recent 52wk high of $0.80 and IMO is a good buying opportunity with news of a commercialisation partnership just around the corner.
 
Re: TIS - Tissue Therapies

News this morning of a capital raising. 50c a piece in an 8:1 ratio.
Massive tank down to 55c seen at the moment.
Not surprising. They've promised a lot and have not delivered anything substantial in at least 12 months.
On the upside - commercialisation seems to be well under way and it the driving force behind this cap raising.
They also seem to be widening their expectations of the diabetic and venous ulcer market to 14B USD per year up from 7B.

My thoughts - their corporate governance leaves a lot to be desired. Ideally we should have seen a firm agreement with a commercialisation partner announced before this capital raising. Instead we have what appears to be a flimsy 'talk' with a partner and the board taking advantage of the stock's higher market price on the back of an unchanged intrinsic value.

I'll be staying in this stock because I believe they have an excellent world class product. I wish they had world class managers as well.
 
TISSUE THERAPIES (TIS) - AUSTRALIA'S NEXT CSL?

PRODUCT

VitroGro is a patented synthetic protein formulation that substantially accelerates skin cell growth and migration, the essential elements of tissue repair and wound healing;

There is no comparable technology available for wound healing and therefore a substantial unmet need;

As a synthetic product not derived from human or animal tissue, there is no risk of transmitting animal diseases to humans.

VitroGro has already been classified as a medical device in Canada and Europe, thus avoiding any need for multiple phase human trials there. Approval is based on only one clinical trial. One trial has already been completed successfully in US and Australia. A second trial is under way and is due for completion by June 2011.The US classification as a device is also expected by June 2011.

The TIS Board believes VitroGro offers attractive price/performance to patients and health care providers, at substantial profit to TIS and its future partners.

Only a few micrograms is required for each dressing, meaning relatively small scale production capacity (and cost) to meet market needs.

MARKET

The TIS Board estimates that by the end of 2014, the global market for the treatment of diabetic, venous and pressure ulcers could potentially exceed US$30 billion.

This market is expected to grow by approximately 25% per annum in the future.

Diabetic ulcers alone result in more than 1 million lower limb amputations each year. Clinical trial results from Canada and Australia found that VitroGro can substantially increase the incidence of complete healing and reduce treatment time for diabetic and venous ulcers, as well as being more cost effective than currently available treatments.

There are not many Australian companies that will ever have the profitability and beneficial impact that TIS will if they achieve their plans. They are within 12 months of starting to prevent hundreds of thousands of lower limb amputations!

TIS is also targeting other markets, including the treatment of acute wounds such as burns, surgical incisions and skin graft donor sites. Pharmacy and consumer applications including minor wound dressings, creams and lotions are also targeted.

TRIALS

Clinical trial results from Canada and Australia confirm that VitroGro can substantially increase the incidence of complete healing and reduce treatment time for diabetic and venous ulcers, as well as being more cost effective than currently available treatments.

Another trial is currently under way, and is being conducted at 5 sites; two in Wales and three in Australia. This is expected to be completed by June 2011, with results soon after. The results will be used for applications for approval for sale in the EU as well as the rest of the world. Expectations are for >50% complete healing rate.

PARTNERSHIP AND SALES

TIS is in negotiations with a shortlist of prospective large, international commercial partners for the world wide launch of VitroGro wound healing products for ulcers. These include a number of the largest wound and healthcare companies in the world. (TIS originally planned to complete a partnership deal in the first quarter of this year, but decided to strengthen its bargaining position by not rushing such a deal. Its bargaining position should be strengthened by a recent capital raising, and imminent completion of the final trial and US classification as a medical device.)

TIS is targeting sales launch in Europe (>25% of the world market) within one year, and in the US by 2013 for venous ulcers and 2014 for diabetic and pressure ulcers. The rest of world will be staged from late 2012.

My view is that TIS will conclude a partnership agreement by Sept/Oct 2011, to fit with their sales plan. Prospective partners have a strong incentive to not let this product escape them (based on the market size for ulcers and product effectiveness).

PROFITABILITY

TIS will own the patents and approvals, and will undertake manufacturing. It will use partners for marketing and sales, bringing in milestone payments and royalties.

TIS's total equity is only $19M post capital raising, and approximately 171 million shares on issue. Its market cap is currently just under $90M.

Assuming it can arrange 10% royalties and capture 25% of the December 2014 market (not a stretch considering VitroGro's competitive position), potential revenues just from ulcers are $750 million at a likely very high margin. Assuming 50% NPAT margin, EPS of $2.20 from 2015 relate to the existing 50c share price.

The upside is huge considering the potential for higher market share, market growth rate of 25%, higher margins, and other large markets for the product.

Having invested in and followed TIS for five years now I believe it has one of the best Biotech products to ever originate in Australia. Its product is within one year of launch in Europe and will have major benefits, preventing hundreds of thousands of sufferers of presently incurable ulcers having their limbs amputated.

Above is a brief outline of some of the key characteristics which make TIS so compelling as an investment on a short, medium and long-term outlook. I trust that you will then see enough potential to research it yourself and make your own decision. There is only a short window of opportunity before milestone after milestone occurs over the next 12 months.
 
Re: TISSUE THERAPIES (TIS) - AUSTRALIA'S NEXT CSL?

hunter22 said:
One trial has already been completed successfully in US and Australia. A second trial is under way and is due for completion by June 2011.The US classification as a device is also expected by June 2011.
Click to expand...

Running a bit late, so the results of the trial must be ready for release very soon. May be a coinicidence but there was a surge in the price yesterday and today (up 23% in the 2 days) with strong volume. Not believing in such coincidences, I entered again yesterday and topped up today.

Cheers
Country Lad
 
Top